ABSTRACT
Although the literature is limited, early evidence suggests that patients with chronic kidney disease, end-stage kidney disease, and kidney transplant recipients are at increased risk for severe COVID-19 disease and death. Hence, management should focus on both infection prevention and treatment. There is currently a lack of evidence and guideline recommendations on optimal management of immunosuppression in kidney transplant recipients with COVID-19 infection. This article focuses on the prevention and management of COVID-19 in patients with chronic kidney disease, patients with end-stage kidney disease on home hemodialysis and peritoneal dialysis, and kidney transplant recipients.
- Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.
- Yeshwanter Radhakrishnan, MD
- Mohamed Hassanein, MD, Fellow
- Brian Stephany, MD⇑
- Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic
- Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
- Correspondence:
Brian Stephany, MD, Department of Nephrology and Hypertension, Q7, 9500 Euclid Ave, Cleveland Clinic, Cleveland, OH 44195; STEPHAB{at}ccf.org
ABSTRACT
Although the literature is limited, early evidence suggests that patients with chronic kidney disease, end-stage kidney disease, and kidney transplant recipients are at increased risk for severe COVID-19 disease and death. Hence, management should focus on both infection prevention and treatment. There is currently a lack of evidence and guideline recommendations on optimal management of immunosuppression in kidney transplant recipients with COVID-19 infection. This article focuses on the prevention and management of COVID-19 in patients with chronic kidney disease, patients with end-stage kidney disease on home hemodialysis and peritoneal dialysis, and kidney transplant recipients.
- Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.